\-\ Texto\\:\\ \ \(0\)\
\-\ labs\\:\ \(4\)\
\-\ na\\ 142\ \(0\)\
\-\ cl\\ 108\ \(0\)\
\-\ co2\\ 25\ \(0\)\
\-\ glu\\ 104\ \(0\)\
\-\ bun\\ 21\ \(0\)\
\-\ cr\\ 1\\.1\ \(0\)\
\-\ ca\\ 9\\.6\ \(0\)\
\-\ alk\\ phos\\ 81\ \(0\)\
\-\ iron\\ 27\ \(0\)\
\-\ tibc\\ 222\ \(0\)\
\-\ ironsat\\ 12\\.2\ \(0\)\
\-\ ferritin\\ 250\ \(0\)\
\-\ pth\\ 61\\.0\ \(0\)\
\-\ axial\\ flair\\,\\ t1\\,\\ and\\ t2\\ mr\\ images\\ through\\ the\\ brain\\ demonstrate\\ mixed\\ high\\ and\\ low\\ t1\\ signal\\ abnormalities\\ in\\ the\\ dentate\\ nuclei\\ of\\ the\\ cerebellum\\,\\ caudate\\ nuclei\\,\\ pallidum\\ and\\ thalami\\.\\ \\ these\\ lesions\\ are\\ fairly\\ symmetric\\,\\ and\\ correspond\\ to\\ \\ areas\\ of\\ calcification\\ seen\\ on\\ previous\\ ct\\.\ \(0\)\
\-\ fahr\\ disease\ \(0\)\
\-\ basal\\ ganglia\\ calcification\ \(8\)\
\-\ idiopathic\\/physiologic\ \(0\)\
\-\ endocrine\ \(38\)\
\-\ \\Â\\»pseudohypoparathyroidism\\ and\\ hypoparathyroidism\ \(0\)\
\-\ \\Â\\»hyperparathyroidism\ \(0\)\
\-\ \\Â\\»hypothyroidism\ \(0\)\
\-\ metabolic\ \(105\)\
\-\ \\Â\\»fahr\ \(0\)\
\-\ \\Â\\»leigh\ \(0\)\
\-\ \\Â\\»mitochondrial\\ cytopathies\ \(0\)\
\-\ congenital\\/developmental\\:\\ \ \(0\)\
\-\ \\Â\\»tuberous\\ sclerosis\\ \ \(0\)\
\-\ \\Â\\»down\\ syndrome\\ \ \(0\)\
\-\ \\Â\\»neurofibromatosis\\ \ \(0\)\
\-\ \\Â\\»familial\\ idiopathic\\ symmetric\\ basal\\ ganglia\\ calcification\\ \ \(0\)\
\-\ \\Â\\»hastings\\-james\\ syndrome\\ \ \(0\)\
\-\ \\Â\\»cockayne\\ syndrome\\ \ \(0\)\
\-\ \\Â\\»lipoid\\ proteinosis\\ \ \(0\)\
\-\ \\Â\\»oculocraniosomatic\\ disease\\ \ \(0\)\
\-\ \\Â\\»methemoglobinopathy\\ \ \(0\)\
\-\ postinfectious\\/inflammatory\\:\\ \ \(0\)\
\-\ \\Â\\»congenital\\ \\(torch\\)\\ infections\ \(0\)\
\-\ \\Â\\»neurocysticercosis\ \(0\)\
\-\ \\Â\\»hiv\ \(0\)\
\-\ \\Â\\»measles\ \(0\)\
\-\ \\Â\\»varicella\ \(0\)\
\-\ \\Â\\»pertussis\\ \ \(0\)\
\-\ \\Â\\»coxsackie\\ b\\ virus\ \(0\)\
\-\ \\Â\\»systemic\\ lupus\\ erythematosus\ \(0\)\
\-\ toxic\\:\\ \ \(1\)\
\-\ \\Â\\»childhood\\ leukemia\\ following\\ methotrexate\\ therapy\\ \ \(0\)\
\-\ \\Â\\»status\\ post\\ xrt\\ \ \(0\)\
\-\ \\Â\\»carbon\\ monoxide\\ poisoning\\ \ \(0\)\
\-\ \\Â\\»lead\\ intoxication\\ \ \(0\)\
\-\ \\Â\\»nephrotic\\ syndrome\\ \ \(0\)\
\-\ anoxic\\:\\ \ \(0\)\
\-\ \\Â\\»birth\\ anoxia\\ \ \(0\)\
\-\ \\Â\\»birth\\ hypoxia\\ \ \(0\)\
\-\ \\Â\\»status\\ post\\-cardiovascular\\ event\ \(0\)\
\-\ 64\\ year\\ old\\ male\\ with\\ symptoms\\ of\\ tia\ \(0\)\
\-\ fahr\\ disease\\,\\ or\\ cerebrovascular\\ ferrocalcinosis\\,\\ is\\ an\\ uncommon\\ disorder\\ characterized\\ by\\ extensive\\ basal\\ ganglia\\ calcification\\,\\ and\\ includes\\ familial\\ and\\ idiopathic\\ forms\\.\\ \\ in\\ this\\ case\\,\\ mr\\ images\\ of\\ this\\ patient\\ are\\ submitted\\ to\\ supplement\\ an\\ earlier\\ submission\\ of\\ ct\\ images\\ from\\ the\\ same\\ patient\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ fahr\\:\\ 0\\.27696950597083947\ \(0\)\
\-\ calcification\\:\\ 0\\.18744045522232214\ \(0\)\
\-\ ganglia\\:\\ 0\\.18506220914373064\ \(0\)\
\-\ basal\\:\\ 0\\.16848918162434548\ \(0\)\
\-\ idiopathic\\:\\ 0\\.16655759892173028\ \(0\)\
\-\ syndrome\\:\\ 0\\.15827392425886097\ \(0\)\
\-\ nuclei\\:\\ 0\\.14472965864611437\ \(0\)\
\-\ familial\\:\\ 0\\.14278382212282936\ \(0\)\
\-\ birth\\:\\ 0\\.1172961440843048\ \(0\)\
\-\ symmetric\\:\\ 0\\.11249227359235392\ \(0\)\
\-\ ironsat\\:\\ 0\\.1049638140580949\ \(0\)\
\-\ cytopathies\\:\\ 0\\.1049638140580949\ \(0\)\
\-\ cockayne\\:\\ 0\\.1049638140580949\ \(0\)\
\-\ oculocraniosomatic\\:\\ 0\\.1049638140580949\ \(0\)\
\-\ methemoglobinopathy\\:\\ 0\\.1049638140580949\ \(0\)\
\-\ coxsackie\\:\\ 0\\.1049638140580949\ \(0\)\
\-\ ferrocalcinosis\\:\\ 0\\.1049638140580949\ \(0\)\
\-\ pallidum\\:\\ 0\\.10029852794487724\ \(0\)\
\-\ pseudohypoparathyroidism\\:\\ 0\\.09698845477016416\ \(0\)\
\-\ and\\:\\ 0\\.09493792477078727\ \(0\)\
\-\ lipoid\\:\\ 0\\.09442096254855838\ \(0\)\
\-\ anoxia\\:\\ 0\\.09442096254855838\ \(0\)\
\-\ supplement\\:\\ 0\\.09442096254855838\ \(0\)\
\-\ congenital\\:\\ 0\\.09431797609100748\ \(0\)\
\-\ tibc\\:\\ 0\\.09232316865694648\ \(0\)\
\-\ pertussis\\:\\ 0\\.09232316865694648\ \(0\)\
\-\ nephrotic\\:\\ 0\\.09232316865694648\ \(0\)\
\-\ status\\:\\ 0\\.09160755021399829\ \(0\)\
\-\ images\\:\\ 0\\.09108094310453217\ \(0\)\
\-\ 222\\:\\ 0\\.09054950919387543\ \(0\)\
\-\ dentate\\:\\ 0\\.09054950919387543\ \(0\)\
\-\ ferritin\\:\\ 0\\.0890130954822334\ \(0\)\
\-\ hypoparathyroidism\\:\\ 0\\.0890130954822334\ \(0\)\
\-\ mitochondrial\\:\\ 0\\.0890130954822334\ \(0\)\
\-\ measles\\:\\ 0\\.0890130954822334\ \(0\)\
\-\ proteinosis\\:\\ 0\\.0876578825437288\ \(0\)\
\-\ leigh\\:\\ 0\\.08644560326062763\ \(0\)\
\-\ varicella\\:\\ 0\\.08644560326062763\ \(0\)\
\-\ cerebrovascular\\:\\ 0\\.08644560326062763\ \(0\)\
\-\ glu\\:\\ 0\\.08534896325536537\ \(0\)\
\-\ mr\\:\\ 0\\.08493699415637886\ \(0\)\
\-\ 142\\:\\ 0\\.08434780936901573\ \(0\)\
\-\ neurocysticercosis\\:\\ 0\\.08434780936901573\ \(0\)\
\-\ 108\\:\\ 0\\.08342683707052125\ \(0\)\
\-\ intoxication\\:\\ 0\\.08342683707052125\ \(0\)\
\-\ disease\\:\\ 0\\.08265306266156311\ \(0\)\
\-\ anoxic\\:\\ 0\\.08257414990594468\ \(0\)\
\-\ t1\\:\\ 0\\.08178875861781326\ \(0\)\
\-\ monoxide\\:\\ 0\\.08178031714740995\ \(0\)\
\-\ correspond\\:\\ 0\\.08103773619430264\ \(0\)\
\-\ poisoning\\:\\ 0\\.08103773619430264\ \(0\)\
\-\ torch\\:\\ 0\\.08034018861098793\ \(0\)\
\-\ submission\\:\\ 0\\.08034018861098793\ \(0\)\
\-\ 250\\:\\ 0\\.07906042519722677\ \(0\)\
\-\ carbon\\:\\ 0\\.07906042519722677\ \(0\)\
\-\ tia\\:\\ 0\\.07906042519722677\ \(0\)\
\-\ pth\\:\\ 0\\.077908863792727\ \(0\)\
\-\ erythematosus\\:\\ 0\\.077908863792727\ \(0\)\
\-\ caudate\\:\\ 0\\.07686214148525615\ \(0\)\
\-\ 104\\:\\ 0\\.07590275175109108\ \(0\)\
\-\ virus\\:\\ 0\\.07545147778259048\ \(0\)\
\-\ xrt\\:\\ 0\\.07545147778259048\ \(0\)\
\-\ methotrexate\\:\\ 0\\.07380495785947919\ \(0\)\
\-\ co2\\:\\ 0\\.07306237690637188\ \(0\)\
\-\ thalami\\:\\ 0\\.07306237690637188\ \(0\)\
\-\ cl\\:\\ 0\\.07270831785421694\ \(0\)\
\-\ iron\\:\\ 0\\.07236482932305718\ \(0\)\
\-\ hypoxia\\:\\ 0\\.07236482932305718\ \(0\)\
\-\ post\\:\\ 0\\.0714276251161535\ \(0\)\
\-\ endocrine\\:\\ 0\\.07139191106141468\ \(0\)\
\-\ 81\\:\\ 0\\.06939824467950385\ \(0\)\
\-\ submitted\\:\\ 0\\.06939824467950385\ \(0\)\
\-\ fairly\\:\\ 0\\.0688867821973254\ \(0\)\
\-\ alk\\:\\ 0\\.06863933155716179\ \(0\)\
\-\ hypothyroidism\\:\\ 0\\.0683970907931542\ \(0\)\
\-\ lupus\\:\\ 0\\.0683970907931542\ \(0\)\
\-\ forms\\:\\ 0\\.0683970907931542\ \(0\)\
\-\ cr\\:\\ 0\\.06792739246316033\ \(0\)\
\-\ phos\\:\\ 0\\.06792739246316033\ \(0\)\
\-\ toxic\\:\\ 0\\.06704187785464961\ \(0\)\
\-\ childhood\\:\\ 0\\.06641977979607834\ \(0\)\
\-\ tuberous\\:\\ 0\\.06545231849981867\ \(0\)\
\-\ event\\:\\ 0\\.06545231849981867\ \(0\)\
\-\ neurofibromatosis\\:\\ 0\\.06508701761844113\ \(0\)\
\-\ hiv\\:\\ 0\\.06490862627305394\ \(0\)\
\-\ of\\:\\ 0\\.064221881145624\ \(0\)\
\-\ bun\\:\\ 0\\.06326210634994264\ \(0\)\
\-\ hyperparathyroidism\\:\\ 0\\.06251952539683535\ \(0\)\
\-\ na\\:\\ 0\\.06223541191749204\ \(0\)\
\-\ 64\\:\\ 0\\.061687403047910226\ \(0\)\
\-\ cerebellum\\:\\ 0\\.06030249716055509\ \(0\)\
\-\ characterized\\:\\ 0\\.06030249716055509\ \(0\)\
\-\ leukemia\\:\\ 0\\.05995203317522957\ \(0\)\
\-\ earlier\\:\\ 0\\.05995203317522957\ \(0\)\
\-\ metabolic\\:\\ 0\\.05950075920672896\ \(0\)\
\-\ uncommon\\:\\ 0\\.0593906529952597\ \(0\)\
\-\ lead\\:\\ 0\\.058444420508147576\ \(0\)\
\-\ systemic\\:\\ 0\\.058244310920082365\ \(0\)\
\-\ infections\\:\\ 0\\.05795052445883769\ \(0\)\
\-\ ca\\:\\ 0\\.055998686156013354\ \(0\)\
\-\ flair\\:\\ 0\\.055836626979860936\ \(0\)\
\-\ disorder\\:\\ 0\\.05551919964057676\ \(0\)\
\-\ mixed\\:\\ 0\\.0543304260067006\ \(0\)\
\-\ down\\:\\ 0\\.05331751329327334\ \(0\)\
\-\ 27\\:\\ 0\\.05318895317039999\ \(0\)\
\-\ 21\\:\\ 0\\.05244637221729269\ \(0\)\
\-\ the\\:\\ 0\\.05238582395724847\ \(0\)\
\-\ same\\:\\ 0\\.05191928717834347\ \(0\)\
\-\ includes\\:\\ 0\\.05103801363559918\ \(0\)\
\-\ extensive\\:\\ 0\\.050570436424846994\ \(0\)\
\-\ an\\:\\ 0\\.05019680578127995\ \(0\)\
\-\ ct\\:\\ 0\\.04997532165970949\ \(0\)\
\-\ are\\:\\ 0\\.049810596385195076\ \(0\)\
\-\ previous\\:\\ 0\\.0495947665163436\ \(0\)\
\-\ abnormalities\\:\\ 0\\.047543840352646\ \(0\)\
\-\ sclerosis\\:\\ 0\\.04675000759411126\ \(0\)\
\-\ 25\\:\\ 0\\.04649711804517515\ \(0\)\
\-\ labs\\:\\ 0\\.04547216681571158\ \(0\)\
\-\ this\\:\\ 0\\.045106375122727485\ \(0\)\
\-\ areas\\:\\ 0\\.044561256617809394\ \(0\)\
\-\ patient\\:\\ 0\\.042695199530201525\ \(0\)\
\-\ brain\\:\\ 0\\.040916358324747576\ \(0\)\
\-\ following\\:\\ 0\\.03937444592182096\ \(0\)\
\-\ through\\:\\ 0\\.039070639195307025\ \(0\)\
\-\ axial\\:\\ 0\\.037912833008404846\ \(0\)\
\-\ t2\\:\\ 0\\.037761325184117955\ \(0\)\
\-\ therapy\\:\\ 0\\.03771126269196814\ \(0\)\
\-\ lesions\\:\\ 0\\.03769462348256942\ \(0\)\
\-\ low\\:\\ 0\\.03766141707772048\ \(0\)\
\-\ high\\:\\ 0\\.03730233510179693\ \(0\)\
\-\ signal\\:\\ 0\\.037206317760497105\ \(0\)\
\-\ these\\:\\ 0\\.03706377760080325\ \(0\)\
\-\ symptoms\\:\\ 0\\.035911466692261654\ \(0\)\
\-\ demonstrate\\:\\ 0\\.034121544312993364\ \(0\)\
\-\ case\\:\\ 0\\.03297404648307019\ \(0\)\
\-\ to\\:\\ 0\\.0328169796065106\ \(0\)\
\-\ in\\:\\ 0\\.03265545450085365\ \(0\)\
\-\ seen\\:\\ 0\\.03090017936114943\ \(0\)\
\-\ male\\:\\ 0\\.029222993078482903\ \(0\)\
\-\ by\\:\\ 0\\.027872204678119357\ \(0\)\
\-\ from\\:\\ 0\\.02606723082408419\ \(0\)\
\-\ or\\:\\ 0\\.022833065110944992\ \(0\)\
\-\ year\\:\\ 0\\.020227252936835468\ \(0\)\
\-\ on\\:\\ 0\\.01982273802246551\ \(0\)\
\-\ old\\:\\ 0\\.01942516465672776\ \(0\)\
\-\ is\\:\\ 0\\.017974446876939016\ \(0\)\
\-\ with\\:\\ 0\\.012852050740861055\ \(0\)\
